Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73

Andrea Tannapfel(Leipzig University), Brigitte M. Pützer(University of Rostock)

Carcinogenesis

November 4, 2007

10.1093/carcin/bgm236

Cited by 46

Related Papers

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

|The Lancet Oncology|2016|738

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

|Annals of Oncology|2016|344

<i>TFAP2E–DKK4</i> and Chemoresistance in Colorectal Cancer

|New England Journal of Medicine|2012|184

Expression of p73 and Its Relation to Histopathology and Prognosis in Hepatocellular Carcinoma

|JNCI Journal of the National Cancer Institute|1999|162

INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas

|Oncogene|2001|132